Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled IMVT-1402 study in adults with CIDP
2024-517614-14-00Phase 2Authorised
- Sponsor
- Immunovant, Inc.
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 2 trial of IMVT-1402, sponsored by Immunovant, Inc. Planned start Dec 2025; status: authorised.
02
Drugs
IMVT-1402
Beyond the preview
Go deeper on 2024-517614-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517614-14-00.